Analyst Price Targets — REX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 26, 2024 4:05 pm | Jordan Levy | Truist Financial | $60.00 | $47.50 | StreetInsider | REX American Resources (REX) PT Lowered to $60 at Truist Securities |
| May 30, 2024 7:08 am | Jordan Levy | Truist Financial | $65.00 | $51.09 | StreetInsider | REX American Resources (REX) PT Lowered to $65 at Truist Securities |
| April 12, 2024 6:17 am | Jordan Levy | Truist Financial | $70.00 | $57.12 | StreetInsider | REX American Resources (REX) PT Raised to $70 at Truist Securities |
This site can’t be displayed in an embedded view
Some publishers block loading inside other sites for security reasons. You can open the article in a new tab instead.
Latest News for REX

Investor demand for AI chip manufacturers has surged this year. The industry is expected to reach revenues of $1.3 trillion in 2026, according to Yahoo Finance, driven by a global AI infrastructure buildout and a bottleneck for AI semiconductors and hardware.

MIAMI--(BUSINESS WIRE)--REX Shares ("REX") and Tuttle Capital Management ("TCM") today announce the launch of the T-REX 2X Long SKHY Daily Target ETF (NYSE Arca: HYNX), a leveraged ETF providing 2x daily long exposure to the SK hynix American Depositary Receipts (ADRs) (SKHY). HYNX is available in pre-market trading beginning at 4:00 a.m. ET. HYNX is designed to deliver 200% of the daily performance of the SK hynix…

According to ETF Database, the REX Drone ETF (DRNZ) fund attracted approximately $11.28 million in inflows during the first week of the month. An additional $4.6 million arrived on July 7, bringing its five-day net inflows to $15.88 million.

This ethanol and co-products supplier reported a notable insider sale amid a year of strong share price gains and steady sector demand.

SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today announced preclinical data for REX-8756, an oral, potent and selective STAT6 inhibitor, is being presented at two upcoming scientific congresses. At the European Association of Allergy and Clinical Immunology (EAACI) Congress…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for REX.
U.S. House Trading
No House trades found for REX.
Options Chain Settings
Changes apply instantly as you toggle. Tap Done when finished.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.
